<unk><unk>  β<unk>  agonists (LABAs, more specifically,<unk><unk>  β2 adrenergic receptor agonists) are usually prescribed for moderate-to-severe persistent asthma patients or patients with chronic obstructive pulmonary disease (COPD). They are designed to reduce the need for shorter-acting β2 agonists such as salbutamol (albuterol), as they have a duration of action of approximately 12 hours in comparison with the 4-to-6-hour duration of salbutamol, making them candidates for sparing high doses of corticosteroids or treating nocturnal asthma and providing symptomatic improvement in patients with COPD. With the exception of formoterol,<unk><unk>  β2 agonists are not recommended for the treatment of acute asthma exacerbations because of their slower onset of action compared to salbutamol. Their<unk>  duration of action is due to the addition of a<unk> , lipophilic side-chain that binds to an exosite on adrenergic receptors. This allows the active portion of the molecule to continuously bind and unbind at β2 receptors in the smooth muscle in the lungs.
Long-acting beta-adrenoceptor agonist
Adrenergic blocking agent
Adrenergic release inhibitor
Norepinephrine–dopamine releasing agent
Serotonin–norepinephrine–dopamine releasing agent
Alpha-adrenergic agonist
Beta-adrenergic agonist
Beta2-adrenergic agonist